Develops antibody medicines for people with autoimmune diseases, including candidates for IgA nephropathy, rheumatoid arthritis and dermatomyositis.
10-K for FY2025, filed Mar 6, 2026 8-K, filed Nov 13, 2026We are a clinical-stage biopharmaceutical company developing novel biologic therapies for patients living with autoimmune diseases. Our…View ↗
Our lead product candidate, JADE101, is a monoclonal antibody (“mAb”) targeting a cytokine called “A PRoliferation Inducing Ligand”…View ↗
We have a third mAb program, JADE301 (formerly JADE-003), designed to target an undisclosed pathway, for which we are conducting…View ↗
JADE301: anti-IFN-b monoclonal antibody for dermatomyositisView ↗
No revenue reported yet.
10-K for FY2025, filed Mar 6, 2026
10-Q for Q3 FY2026, filed Nov 13, 2026
−$35.1MView ↗
8-K, filed Nov 13, 2026
JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026View ↗
8-K, filed Jul 1, 2026
On June 29, 2026, Jade Biosciences, Inc. (the “Company”) entered into a License Agreement (the “JADE301 License Agreement”) with Paragon…View ↗
From PAH to autoimmune diseases
The older report described Aerovate’s focus as developing an inhaled drug for pulmonary arterial hypertension. The latest report describes Jade as developing antibody therapies for autoimmune diseases.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 6, 2026We are a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare…View ↗
Competes with Otsuka, Novartis, Vera Therapeutics, Vertex, and Climb Bio
10-K for FY2025, filed Mar 6, 2026There is one biologic approved for the treatment of IgAN, sibeprenlimab, which is marketed as Voyxact by Otsuka. There are four small…View ↗
Loading...